However, there are limitations in the study of IGF2BP3 in breast cancer, including a retrospective design that may introduce biases, lack of functional studies on IGF2BP3’s role in cancer progression, limited evidence for its prognostic value, and the relatively small number of positive cases. The gene discussed is IGF2BP3; the disease is breast carcinoma.